参芪扶正注射液联合化疗对急性淋巴细胞白血病患者细胞免疫功能的影响

Effect of Shenqi Fuzheng Znjection Combined with chemotherapy on cellular immune function in patients with acute lymphoblastic leukemia

目的:观察分析参芪扶正注射液对急性淋巴细胞白血病患者化疗前后骨髓造血功能和免疫功能的影响。方法:选择急性淋巴细胞白血病患者92例,随机分为观察组和对照组各46例。两组均接受VDCP化疗,观察组在此基础上加用参芪扶正注射液,观察两组患者治疗前后T细胞亚群和B细胞亚群的变化情况。结果:经治疗,观察组有效率为86.96%,对照组有效率为80.43%,两组比较差异无统计学意义(P>0.05)。观察组患者化疗后T淋巴细胞亚群CD_3^+、CD_4^+、CD_4^+/CD_8^+比值均优于对照组(P<0.05)。两组患者治疗后B淋巴细胞CD3-CD+19水平比较差异均无统计学意义(P>0.05)。结论:联合应用参芪扶正注射液治疗急性淋巴白血病可降低对患者免疫功能影响。

Objective To observe the effects of Shenqi Fuzheng Injection on bone marrow hematopoietic function and immune function in patients with acute lymphoblastic leukemia before and after chemotherapy. Method A total of 92 patients with acute lymphoblastic leukemia were selected and randomly divided into the observation group and the control group. Each group consisted of 46 patients. Both groups received VDCP chemotherapy. The observation group added Shenqi Fuzheng Injection on the basis of that. The changes of T cell subsets and B cell subsets before and after treatment in the two groups. Results After treatment,the effective rate of observation group was 86. 96%,and the control group was 80. 43%. The difference was not statistically significant（ P〉0. 05）. The ratios of CD3^＋,CD4^＋ and CD4^＋/CD8^＋ in T lymphocyte subsets in the observation group were better than those in the control group after chemotherapy（ P〈0. 05）. The levels of CD3-CD＋19 were significantly different between the two groups after treatment. No statistical significance（ P〉0. 05）. Conclusion The combination of Shenqi Fuzheng Injection in the treatment of acute lymphoblastic leukemia patients can reduce the impact on the patient＇s immune function.